BCDA
BIOCARDIA, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $0.90 | — |
| Renaissance Technologies | Q2 2026(8Q snapshot) | 1Q | $1.09 | $0.90 | -17% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q1 2026 | Q2 2026 | → $1.01 | -14% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BioCardia, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.
- Form 40001437749-26-020044Jun 9, 2026
- Form 40001437749-26-018125May 21, 2026
- Form 40001437749-26-017672May 18, 2026
- Form 40001437749-26-017459May 15, 2026
- Form 40001437749-26-013944Apr 29, 2026
- Form 40001437749-26-013052Apr 22, 2026
- Form 40001437749-26-009986Mar 26, 2026
- Form 40001437749-26-003027Feb 4, 2026
- Form 40001437749-26-001643Jan 21, 2026
- Form 40001437749-25-038200Dec 17, 2025
- Form 40001437749-25-037475Dec 10, 2025
- Form 40001437749-25-037474Dec 10, 2025
- Form 40001437749-25-037473Dec 10, 2025
- Form 40001437749-25-037472Dec 10, 2025
- Form 40001437749-25-037471Dec 10, 2025
Fundamentals
XBRL · BIOCARDIA, INC.Annual figures sourced directly from BIOCARDIA, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BioCardia, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KJun 8, 2026
- 8-KFORM 8-KJun 5, 2026
- 8-KFORM 8-KMay 28, 2026
- 8-KFORM 8-KMay 21, 2026
- 8-KFORM 8-KMay 15, 2026
- 10-QFORM 10-QMay 15, 2026
- 8-KFORM 8-KMay 8, 2026
- 8-KFORM 8-KApr 28, 2026
- 8-KFORM 8-KApr 20, 2026
- 8-KFORM 8-KApr 15, 2026
- 8-KFORM 8-KApr 2, 2026
- 8-KFORM 8-KMar 24, 2026
- 10-KFORM 10-KMar 24, 2026
- 8-KFORM 8-KMar 17, 2026
- 8-KFORM 8-KMar 3, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $1.09 | $0.90 | -17% |
| Citadel Advisors | Q1 2026 | open | $1.17 | $0.90 | -23% |
| Two Sigma Investments | Q1 2026 | Q2 2026 | $1.17 | $1.01 | -14% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.